Categories AlphaGraphs, Earnings, Other Industries

Chevron Q2 earnings get a boost from Anadarko deal termination

In the midst of volatile oil prices and geo-political conditions, Chevron (NYSE: CVX) reported 8% decline in total revenues and other income in the second quarter of 2019 to $38.85 billion, which was lower than the street estimate of $40.55 billion.

The San Ramon, California-based oil giant said its earnings for the second quarter stood at $2.27 per share, compared to $1.78 per share in the same quarter last year. Earnings were boosted by $740 million associated with the Anadarko merger termination fee. Analysts were expecting flat year-over-year EPS growth.

Chevron (NYSE: CVX) reported 8% decline in total revenues and other income in the second quarter of 2019 to $38.85 billion, which was lower than the street estimate of $40.55 billion.

CVX stock gained 1% post the Q2 results. Chevron’s shares have dropped over 2% in the trailing 52 weeks but have gained 14% thus far this year. 

CEO Michael Wirth said, “Net oil-equivalent production was the highest in the company’s history, driven by continued growth in the Permian Basin and at Wheatstone in Australia.”

Worldwide net oil-equivalent production was 3.08 million barrels per day in second-quarter 2019, an increase of 9% from a year ago.

READ: Honda Motor begins fiscal 2020 on a dull note, sells fewer cars in North America

In May, Chevron completed the acquisition of Pasadena Refining System Inc. for $350 million. The same month, the company also decided to not pursue the acquisition of Anadarko Petroleum Corp. (NYSE: APC). Anadarko has agreed to be acquired by Occidental Petroleum (NYSE: OXY).

Earlier today, rival ExxonMobil (NYSE: XOM) reported a 21% dip in earnings for the second quarter due to poor performance from the downstream and chemical division. However, the results exceeded analysts’ expectations.

Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!

Most Popular

Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO

Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training

INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues

Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came

Riding the AI wave, Nvidia looks set to stay on the high-growth path

After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on

Tags

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top